Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA

Zénó Ajtay, Fortunato Scalera, Attila Cziráki, Iván Horváth, Lajos Papp, Endre Sulyok, Csaba Szabo, Jens Martens-Lobenhoffer, Friedemann Awiszus, Stefanie M. Bode-Böger

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD). The potential effect of percutaneous coronary intervention (PCI) with stent placement on ADMA plasma level in CHD patients has not yet been investigated. Concentrations of ADMA, L-arginine, symmetric dimethylarginine (SDMA), and L-ornithine were measured in the plasma of 30 CHD patients 24 h before, and 1 h, 5 days, and 30 days following PCI with bare-metal stent or drug-eluting stent placement (stent group) and in the plasma of 20 patients without CHD who underwent angiography alone (control group). A repeated measures ANOVA revealed the significant time by group interaction for ADMA (F=12.8, p<0.0001), SDMA (F=5.5, p=0.013), L-ornithine (F=12.5, p<0.0001), L-aginine (F=4.7, p=0.013) and L-arginine/ADMA ratio (F=7.1, p<0.001). Post-hoc ANOVAs showed that this interaction was due to the fact that control patients without stent placement responded to the coronary angiography with a significant increase in ADMA (F=4.4, p=0.009), SDMA (F=4.7, p=0.007) and L-ornithine (F=28.3, p<0.0001) levels, whereas the stent implantation independent of the stent type used significantly reduced the cardiovascular risk factor ADMA (F=10.8, p<0.0001). Thus, the current study demonstrates that in patients with CHD, PCI stent placement markedly decreases the plasma level of cardiovascular risk factor ADMA. Coronary angiography alone results in an increase of ADMA. We conclude that the stent effect on ADMA level cannot be explained by unspecific effects of the coronary angiography and is independent of the stent type used.

Original languageEnglish (US)
Pages (from-to)651-657
Number of pages7
JournalInternational Journal of Molecular Medicine
Volume23
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Nitric Oxide Synthase
Stents
Coronary Disease
Ornithine
Percutaneous Coronary Intervention
Coronary Angiography
Arginine
Analysis of Variance
N,N-dimethylarginine
Drug-Eluting Stents
Angiography
Metals
Control Groups

Keywords

  • Angiography
  • L-arginine
  • L-arginine/asymmetrical dimethylarginine ratio
  • Risk factor

ASJC Scopus subject areas

  • Genetics

Cite this

Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA. / Ajtay, Zénó; Scalera, Fortunato; Cziráki, Attila; Horváth, Iván; Papp, Lajos; Sulyok, Endre; Szabo, Csaba; Martens-Lobenhoffer, Jens; Awiszus, Friedemann; Bode-Böger, Stefanie M.

In: International Journal of Molecular Medicine, Vol. 23, No. 5, 2009, p. 651-657.

Research output: Contribution to journalArticle

Ajtay, Z, Scalera, F, Cziráki, A, Horváth, I, Papp, L, Sulyok, E, Szabo, C, Martens-Lobenhoffer, J, Awiszus, F & Bode-Böger, SM 2009, 'Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA', International Journal of Molecular Medicine, vol. 23, no. 5, pp. 651-657. https://doi.org/10.3892/ijmm_00000176
Ajtay, Zénó ; Scalera, Fortunato ; Cziráki, Attila ; Horváth, Iván ; Papp, Lajos ; Sulyok, Endre ; Szabo, Csaba ; Martens-Lobenhoffer, Jens ; Awiszus, Friedemann ; Bode-Böger, Stefanie M. / Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA. In: International Journal of Molecular Medicine. 2009 ; Vol. 23, No. 5. pp. 651-657.
@article{06d185cffac2466388400918284ad961,
title = "Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA",
abstract = "The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD). The potential effect of percutaneous coronary intervention (PCI) with stent placement on ADMA plasma level in CHD patients has not yet been investigated. Concentrations of ADMA, L-arginine, symmetric dimethylarginine (SDMA), and L-ornithine were measured in the plasma of 30 CHD patients 24 h before, and 1 h, 5 days, and 30 days following PCI with bare-metal stent or drug-eluting stent placement (stent group) and in the plasma of 20 patients without CHD who underwent angiography alone (control group). A repeated measures ANOVA revealed the significant time by group interaction for ADMA (F=12.8, p<0.0001), SDMA (F=5.5, p=0.013), L-ornithine (F=12.5, p<0.0001), L-aginine (F=4.7, p=0.013) and L-arginine/ADMA ratio (F=7.1, p<0.001). Post-hoc ANOVAs showed that this interaction was due to the fact that control patients without stent placement responded to the coronary angiography with a significant increase in ADMA (F=4.4, p=0.009), SDMA (F=4.7, p=0.007) and L-ornithine (F=28.3, p<0.0001) levels, whereas the stent implantation independent of the stent type used significantly reduced the cardiovascular risk factor ADMA (F=10.8, p<0.0001). Thus, the current study demonstrates that in patients with CHD, PCI stent placement markedly decreases the plasma level of cardiovascular risk factor ADMA. Coronary angiography alone results in an increase of ADMA. We conclude that the stent effect on ADMA level cannot be explained by unspecific effects of the coronary angiography and is independent of the stent type used.",
keywords = "Angiography, L-arginine, L-arginine/asymmetrical dimethylarginine ratio, Risk factor",
author = "Z{\'e}n{\'o} Ajtay and Fortunato Scalera and Attila Czir{\'a}ki and Iv{\'a}n Horv{\'a}th and Lajos Papp and Endre Sulyok and Csaba Szabo and Jens Martens-Lobenhoffer and Friedemann Awiszus and Bode-B{\"o}ger, {Stefanie M.}",
year = "2009",
doi = "10.3892/ijmm_00000176",
language = "English (US)",
volume = "23",
pages = "651--657",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA

AU - Ajtay, Zénó

AU - Scalera, Fortunato

AU - Cziráki, Attila

AU - Horváth, Iván

AU - Papp, Lajos

AU - Sulyok, Endre

AU - Szabo, Csaba

AU - Martens-Lobenhoffer, Jens

AU - Awiszus, Friedemann

AU - Bode-Böger, Stefanie M.

PY - 2009

Y1 - 2009

N2 - The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD). The potential effect of percutaneous coronary intervention (PCI) with stent placement on ADMA plasma level in CHD patients has not yet been investigated. Concentrations of ADMA, L-arginine, symmetric dimethylarginine (SDMA), and L-ornithine were measured in the plasma of 30 CHD patients 24 h before, and 1 h, 5 days, and 30 days following PCI with bare-metal stent or drug-eluting stent placement (stent group) and in the plasma of 20 patients without CHD who underwent angiography alone (control group). A repeated measures ANOVA revealed the significant time by group interaction for ADMA (F=12.8, p<0.0001), SDMA (F=5.5, p=0.013), L-ornithine (F=12.5, p<0.0001), L-aginine (F=4.7, p=0.013) and L-arginine/ADMA ratio (F=7.1, p<0.001). Post-hoc ANOVAs showed that this interaction was due to the fact that control patients without stent placement responded to the coronary angiography with a significant increase in ADMA (F=4.4, p=0.009), SDMA (F=4.7, p=0.007) and L-ornithine (F=28.3, p<0.0001) levels, whereas the stent implantation independent of the stent type used significantly reduced the cardiovascular risk factor ADMA (F=10.8, p<0.0001). Thus, the current study demonstrates that in patients with CHD, PCI stent placement markedly decreases the plasma level of cardiovascular risk factor ADMA. Coronary angiography alone results in an increase of ADMA. We conclude that the stent effect on ADMA level cannot be explained by unspecific effects of the coronary angiography and is independent of the stent type used.

AB - The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD). The potential effect of percutaneous coronary intervention (PCI) with stent placement on ADMA plasma level in CHD patients has not yet been investigated. Concentrations of ADMA, L-arginine, symmetric dimethylarginine (SDMA), and L-ornithine were measured in the plasma of 30 CHD patients 24 h before, and 1 h, 5 days, and 30 days following PCI with bare-metal stent or drug-eluting stent placement (stent group) and in the plasma of 20 patients without CHD who underwent angiography alone (control group). A repeated measures ANOVA revealed the significant time by group interaction for ADMA (F=12.8, p<0.0001), SDMA (F=5.5, p=0.013), L-ornithine (F=12.5, p<0.0001), L-aginine (F=4.7, p=0.013) and L-arginine/ADMA ratio (F=7.1, p<0.001). Post-hoc ANOVAs showed that this interaction was due to the fact that control patients without stent placement responded to the coronary angiography with a significant increase in ADMA (F=4.4, p=0.009), SDMA (F=4.7, p=0.007) and L-ornithine (F=28.3, p<0.0001) levels, whereas the stent implantation independent of the stent type used significantly reduced the cardiovascular risk factor ADMA (F=10.8, p<0.0001). Thus, the current study demonstrates that in patients with CHD, PCI stent placement markedly decreases the plasma level of cardiovascular risk factor ADMA. Coronary angiography alone results in an increase of ADMA. We conclude that the stent effect on ADMA level cannot be explained by unspecific effects of the coronary angiography and is independent of the stent type used.

KW - Angiography

KW - L-arginine

KW - L-arginine/asymmetrical dimethylarginine ratio

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=67649429267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649429267&partnerID=8YFLogxK

U2 - 10.3892/ijmm_00000176

DO - 10.3892/ijmm_00000176

M3 - Article

C2 - 19360324

AN - SCOPUS:67649429267

VL - 23

SP - 651

EP - 657

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 5

ER -